Cimzia (certolizumab)
By Business Review Editor
Pharma Deals Review: Vol 2006 Issue 77 (Table of Contents)
Published: 6 Nov-2006
DOI: 10.3833/pdr.v2006.i77.438 ISSN: 1756-7874
Section: Deal Trackers
Fulltext:
Abstract
Certolizumab pegol (CDP 870) is a PEGylated fragment of a humanised anti-TNF-α monoclonal antibody (MAb) in late-stage development for Crohn’s disease (CD) and rheumatoid arthritis (RA), and in Phase II trials for psoriasis...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS